Cargando…

Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirabelli, Carmen, Wotring, Jesse W., Zhang, Charles J., McCarty, Sean M., Fursmidt, Reid, Pretto, Carla D., Qiao, Yuanyuan, Zhang, Yuping, Frum, Tristan, Kadambi, Namrata S., Amin, Anya T., O’Meara, Teresa R., Spence, Jason R., Huang, Jessie, Alysandratos, Konstantinos D., Kotton, Darrell N., Handelman, Samuel K., Wobus, Christiane E., Weatherwax, Kevin J., Mashour, George A., O’Meara, Matthew J., Chinnaiyan, Arul M., Sexton, Jonathan Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433531/
https://www.ncbi.nlm.nih.gov/pubmed/34413211
http://dx.doi.org/10.1073/pnas.2105815118
_version_ 1783751391643172864
author Mirabelli, Carmen
Wotring, Jesse W.
Zhang, Charles J.
McCarty, Sean M.
Fursmidt, Reid
Pretto, Carla D.
Qiao, Yuanyuan
Zhang, Yuping
Frum, Tristan
Kadambi, Namrata S.
Amin, Anya T.
O’Meara, Teresa R.
Spence, Jason R.
Huang, Jessie
Alysandratos, Konstantinos D.
Kotton, Darrell N.
Handelman, Samuel K.
Wobus, Christiane E.
Weatherwax, Kevin J.
Mashour, George A.
O’Meara, Matthew J.
Chinnaiyan, Arul M.
Sexton, Jonathan Z.
author_facet Mirabelli, Carmen
Wotring, Jesse W.
Zhang, Charles J.
McCarty, Sean M.
Fursmidt, Reid
Pretto, Carla D.
Qiao, Yuanyuan
Zhang, Yuping
Frum, Tristan
Kadambi, Namrata S.
Amin, Anya T.
O’Meara, Teresa R.
Spence, Jason R.
Huang, Jessie
Alysandratos, Konstantinos D.
Kotton, Darrell N.
Handelman, Samuel K.
Wobus, Christiane E.
Weatherwax, Kevin J.
Mashour, George A.
O’Meara, Matthew J.
Chinnaiyan, Arul M.
Sexton, Jonathan Z.
author_sort Mirabelli, Carmen
collection PubMed
description The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10 to 15 y from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 US Food and Drug Administration (FDA)-approved compounds and clinical candidates, we identified 17 hits that inhibited SARS-CoV-2 infection and analyzed their antiviral activity across multiple cell lines, including lymph node carcinoma of the prostate (LNCaP) cells and a physiologically relevant model of alveolar epithelial type 2 cells (iAEC2s). Additionally, we found that inhibitors of the Ras/Raf/MEK/ERK signaling pathway exacerbate SARS-CoV-2 infection in vitro. Notably, we discovered that lactoferrin, a glycoprotein found in secretory fluids including mammalian milk, inhibits SARS-CoV-2 infection in the nanomolar range in all cell models with multiple modes of action, including blockage of virus attachment to cellular heparan sulfate and enhancement of interferon responses. Given its safety profile, lactoferrin is a readily translatable therapeutic option for the management of COVID-19.
format Online
Article
Text
id pubmed-8433531
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher National Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-84335312021-09-28 Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 Mirabelli, Carmen Wotring, Jesse W. Zhang, Charles J. McCarty, Sean M. Fursmidt, Reid Pretto, Carla D. Qiao, Yuanyuan Zhang, Yuping Frum, Tristan Kadambi, Namrata S. Amin, Anya T. O’Meara, Teresa R. Spence, Jason R. Huang, Jessie Alysandratos, Konstantinos D. Kotton, Darrell N. Handelman, Samuel K. Wobus, Christiane E. Weatherwax, Kevin J. Mashour, George A. O’Meara, Matthew J. Chinnaiyan, Arul M. Sexton, Jonathan Z. Proc Natl Acad Sci U S A Biological Sciences The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10 to 15 y from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 US Food and Drug Administration (FDA)-approved compounds and clinical candidates, we identified 17 hits that inhibited SARS-CoV-2 infection and analyzed their antiviral activity across multiple cell lines, including lymph node carcinoma of the prostate (LNCaP) cells and a physiologically relevant model of alveolar epithelial type 2 cells (iAEC2s). Additionally, we found that inhibitors of the Ras/Raf/MEK/ERK signaling pathway exacerbate SARS-CoV-2 infection in vitro. Notably, we discovered that lactoferrin, a glycoprotein found in secretory fluids including mammalian milk, inhibits SARS-CoV-2 infection in the nanomolar range in all cell models with multiple modes of action, including blockage of virus attachment to cellular heparan sulfate and enhancement of interferon responses. Given its safety profile, lactoferrin is a readily translatable therapeutic option for the management of COVID-19. National Academy of Sciences 2021-09-07 2021-08-19 /pmc/articles/PMC8433531/ /pubmed/34413211 http://dx.doi.org/10.1073/pnas.2105815118 Text en Copyright © 2021 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Biological Sciences
Mirabelli, Carmen
Wotring, Jesse W.
Zhang, Charles J.
McCarty, Sean M.
Fursmidt, Reid
Pretto, Carla D.
Qiao, Yuanyuan
Zhang, Yuping
Frum, Tristan
Kadambi, Namrata S.
Amin, Anya T.
O’Meara, Teresa R.
Spence, Jason R.
Huang, Jessie
Alysandratos, Konstantinos D.
Kotton, Darrell N.
Handelman, Samuel K.
Wobus, Christiane E.
Weatherwax, Kevin J.
Mashour, George A.
O’Meara, Matthew J.
Chinnaiyan, Arul M.
Sexton, Jonathan Z.
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
title Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
title_full Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
title_fullStr Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
title_full_unstemmed Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
title_short Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19
title_sort morphological cell profiling of sars-cov-2 infection identifies drug repurposing candidates for covid-19
topic Biological Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8433531/
https://www.ncbi.nlm.nih.gov/pubmed/34413211
http://dx.doi.org/10.1073/pnas.2105815118
work_keys_str_mv AT mirabellicarmen morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT wotringjessew morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT zhangcharlesj morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT mccartyseanm morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT fursmidtreid morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT prettocarlad morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT qiaoyuanyuan morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT zhangyuping morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT frumtristan morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT kadambinamratas morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT aminanyat morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT omearateresar morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT spencejasonr morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT huangjessie morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT alysandratoskonstantinosd morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT kottondarrelln morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT handelmansamuelk morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT wobuschristianee morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT weatherwaxkevinj morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT mashourgeorgea morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT omearamatthewj morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT chinnaiyanarulm morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19
AT sextonjonathanz morphologicalcellprofilingofsarscov2infectionidentifiesdrugrepurposingcandidatesforcovid19